Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial -

Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial
Information type: Randomised controlled trials
Source: Lancet Gastroenterology and Hepatology
Specialities: Allergy and immunology | Gastrointestinal disorders | Nutritional and metabolic disorders | Paediatric and neonatal medicine
Summary
RCT (n= 48) reported that at week 36, more omalizumab-treated children were able to eat at least 2 g of protein from two or more foods previously causing allergic reactions versus placebo (83% vs 33%; OR 10.0; 95% CI, 1.8 to 58.3, P=0.0044).
UKMi comment
In an accompanying comment, the author notes that further studies are needed to investigate whether tolerance is sustained and that not all patients can be treated adequately with omalizumab because of very high levels of serum IgE. This could present a problem in a substantial proportion of children with atopic dermatitis, which often occurs together with food allergy.
Related links: Comment